X4 Pharmaceuticals: Venrock reports 7.6% passive stake
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
X4 Pharmaceuticals, Inc. (XFOR) is the issuer in an amended Schedule 13G reporting that a group beneficially owned 7,644,072 shares, or 7.6%, as of September 30, 2026. The reporting group includes Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, and voting members Nimish Shah and Bong Y. Koh.
The shares were held by the three investment vehicles: 3,502,608 by Venrock Healthcare Capital Partners III, L.P.; 350,567 by VHCP Co-Investment Holdings III, LLC; and 3,790,897 by Venrock Healthcare Capital Partners EG, L.P. Each reporting person reported shared voting and dispositive power over 7,644,072 shares and zero sole voting or dispositive power. The 7.6% calculation used 100,903,502 shares outstanding as of September 30, 2026.
Key Figures
Key Terms
beneficially owned regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.